Prediction of the SARS-CoV-2 (2019-nCoV) 3c-Like Protease (3CLpro) Structure: Virtual Screening Reveals Velpatasvir, Ledipasvir, and Other Drug Repurposing Candidates

F1000Research - United Kingdom
doi 10.12688/f1000research.22457.1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

F1000 Research Ltd

Related search

Prediction of the SARS-CoV-2 (2019-nCoV) 3c-Like Protease (3CLpro) Structure: Virtual Screening Reveals Velpatasvir, Ledipasvir, and Other Drug Repurposing Candidates

2020English

Inhibition of SARS-CoV 3c-Like Protease Activity by Theaflavin-3,3'-Digallate (TF3)

Evidence-based Complementary and Alternative Medicine
Alternative MedicineComplementary
2005English

Virus Against Virus: A Potential Treatment for 2019-nCov (SARS-CoV-2) and Other RNA Viruses

Cell Research
Cell BiologyMolecular Biology
2020English

In Silico Repositioning for Dual Inhibitor Discovery of SARS-CoV-2 (COVID-19) 3c-Like Protease and Papain-Like Peptidase

2020English

Scutellaria Baicalensis Extract and Baicalein Inhibit Replication of SARS-CoV-2 and Its 3c-Like Protease in Vitro

2020English

Comparative Genetic Analysis of the Novel Coronavirus (2019-nCoV/SARS-CoV-2) Receptor ACE2 in Different Populations

Cell Discovery
BiochemistryGeneticsCell BiologyMolecular Biology
2020English

Computational Target-Based Drug Repurposing of Elbasvir, an Antiviral Drug Predicted to Bind Multiple SARS-CoV-2 Proteins

2020English

Characteristics of Flavonoids as Potent MERS ‐CoV 3C‐like Protease Inhibitors

Chemical Biology and Drug Design
BiochemistryOrganic ChemistryDrug DiscoveryMolecular MedicinePharmacology
2019English

Isatin Compounds as Noncovalent SARS Coronavirus 3c-Like Protease Inhibitors

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy